- Details
- Ashish Kamat is joined by Marek Babjuk, Morgan Roupret, and Wassim Kassouf for a rapid-fire debate on the management of small local recurrence low-grade bladder tumors with negative cytology. The patient in this debate is an 81-year-old male with multiple medical comorbidities. Dr. Morgan Roupret argues for formal TURBT with intravesical chemotherapy while Dr. Wassim Kassouf argues for active surv...
|
- Details
- Lydia Makaroff, Stephanie Chisolm, and Alex Filicevas join Ashish Kamat on UroToday's Bladder Cancer Center of Excellence for a round table discussion on the importance of bladder cancer from a patient perspective and recent efforts by The World Bladder Cancer Patient Coalition. Their recently launched evidence generation study, or bladder cancer patient survey, aims to capture bladder cancer pati...
|
- Details
- Ashish Kamat and Sumeet Bhanvadia, discuss the burden and impact of financial toxicity amongst a diverse population in bladder cancer patients. This conversation kicks off with a background on financial toxicity and how it may affect patient outcomes. Dr. Bhanvadia goes on to discuss the social and clinical determinants of financial toxicity among a diverse sample of bladder cancer patients. Dr. B...
|
- Details
- Richard Matulewicz joins Ashish Kamat presenting findings on the association of smoking status on recurrence of non-muscle invasive bladder cancer (NMIBC) in a contemporary cohort of patients with predominantly high-risk, recurrent NMIBC managed with photodynamic enhanced cystoscopy. A retrospective study was conducted in a multi-institutional registry. Smoking has a strong causal association with...
|
- Details
- Stephen Williams joins Ashish Kamat presenting findings on macro and microeconomics of blue light cystoscopy (BLC) with CYSVIEW® in the care of patients with non-muscle invasive bladder cancer, a Urologic Oncology Seminars and Original Investigations publication. The aim of the study was to determine the estimated budget impact to practices that incorporate blue light cystoscopy with hexaminolevul...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a recently published paper, entitled, “ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma.” They discuss the basics of circulating tumor DNA (ctDNA). He specifically discusses how we can use ctDNA to identify molecularly, or microscopic, residual disease. The study shows that ctDNA-positive patients with adjuvant atezolizumab, after surgery...
|
- Details
- Ashish Kamat, MD, MBBS, and Bishoy Faltas, MD, discuss immuno-oncology approaches across the spectrum of urothelial carcinoma. They discuss chemotherapy coupled with immune checkpoint inhibitors and how the combination may benefit patients with urothelial cancers. Further, they discuss the JAVELIN Bladder 100 trial, a randomized 700 patient trial that evaluated maintenance avelumab treatment. Biog...
|
- Details
- In this informative presentation from Andrea Necchi, MD, he presents information related to his goal of finding bladder-sparing treatment options for muscle-invasive bladder cancer (MIBC). Dr. Necchi begins his presentation with a discussion on recent immunotherapy studies for MIBC, the Balar, and IMMUNOPRESERVE studies. He presents evidence that both of these trials have displayed a promising amo...
|
- Details
- Eugene Pietzak, MD, Assistant Attending Surgeon of Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York City received one of the five 2021 Bladder Cancer Advocacy Network (BCAN) New Discoveries Young Investigator Awards for his work in “Defining the Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer.” There are relatively well-established molecul...
|
- Details
- In a presentation, followed by an educational discussion, from Reza Mehrazin, MD, the topic of management of primary urothelial carcinoma is discussed in depth. Dr. Mehrazin began his presentation with epidemiology and risk factors for this aggressive disease. He discussed the risk factor of advanced age (>60 years old) along with other less-known risk factors, such as chronic urethral irritation....
|
